Galapagos CSO hits the exit as the biotech looks to pick up the pieces after FDA's filgotinib rejection
Months after Galapagos cut away broad swaths of its pipeline following a rejection for Gilead-partnered rheumatoid arthritis drug filgotinib, the biotech will now say goodbye to its longtime chief scientific officer as it considers its options moving ahead.
Piet Wigerinck will step down from his role later this year, the company announced on Tuesday. Wigerinck joined in 2008 as the SVP of development, and became the CSO in 2012. He oversaw the discovery of novel targets through to clinical proof-of-concept studies, led the first clinical research in healthy volunteers and was responsible for two Phase II programs for filgotinib, a JAK inhibitor.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.